SG11202007143UA - Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death - Google Patents
Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte deathInfo
- Publication number
- SG11202007143UA SG11202007143UA SG11202007143UA SG11202007143UA SG11202007143UA SG 11202007143U A SG11202007143U A SG 11202007143UA SG 11202007143U A SG11202007143U A SG 11202007143UA SG 11202007143U A SG11202007143U A SG 11202007143UA SG 11202007143U A SG11202007143U A SG 11202007143UA
- Authority
- SG
- Singapore
- Prior art keywords
- reducing
- protein kinase
- liver regeneration
- promoting liver
- hepatocyte death
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154454 | 2018-01-31 | ||
| EP18183692 | 2018-07-16 | ||
| PCT/EP2019/052213 WO2019149738A1 (en) | 2018-01-31 | 2019-01-30 | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007143UA true SG11202007143UA (en) | 2020-08-28 |
Family
ID=65228576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007143UA SG11202007143UA (en) | 2018-01-31 | 2019-01-30 | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11858927B2 (en) |
| EP (1) | EP3746437A1 (en) |
| JP (1) | JP7337813B2 (en) |
| KR (1) | KR20200138166A (en) |
| CN (1) | CN111788195B (en) |
| AU (1) | AU2019216264B2 (en) |
| BR (1) | BR112020015072A2 (en) |
| CA (1) | CA3089678A1 (en) |
| IL (1) | IL276353B2 (en) |
| MA (1) | MA51889A (en) |
| MX (1) | MX2020007954A (en) |
| SG (1) | SG11202007143UA (en) |
| WO (1) | WO2019149738A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019216264B2 (en) | 2018-01-31 | 2023-08-31 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3104246A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| KR20220046584A (en) * | 2019-07-29 | 2022-04-14 | 헤파레게닉스 게엠베하 | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocellular death |
| CN111423443A (en) * | 2020-04-03 | 2020-07-17 | 广州科锐特生物科技有限公司 | Preparation method of 4-amino-7-iodopyrrolo [2,1-f ] [1,2,4] triazine |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| CA3187212A1 (en) * | 2020-07-30 | 2022-02-03 | Torsten Wuestefeld | Method of stimulating proliferation of a cell |
| CN112194661B (en) * | 2020-10-22 | 2021-06-08 | 威海同丰海洋生物科技有限公司 | Preparation method of 4-amino-7-iodopyrrolo [2, l-f ] [ l,2,4] triazine |
| WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| WO2023194443A1 (en) | 2022-04-06 | 2023-10-12 | Heparegenix Gmbh | Pharmaceutical composition for the treatment of colon and lung cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
| WO2003035621A1 (en) | 2001-10-22 | 2003-05-01 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| WO2003037898A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| WO2004058764A1 (en) | 2002-12-27 | 2004-07-15 | Bayer Healthcare Ag | 4-phenyl-pyrimido [4,5-b] indole derivatives |
| FR2876377B1 (en) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | NOVEL 9H-PYRIDO [2,3-B] INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS |
| JP2006282745A (en) | 2005-03-31 | 2006-10-19 | Fuji Photo Film Co Ltd | Cellulose derivative composition, cellulose derivative film, and substituted benzoic acid derivative compound |
| KR20080027775A (en) | 2005-05-17 | 2008-03-28 | 플렉시콘, 인코퍼레이티드 | Pyrrole(2,3-b)pyridine derivatives protein kinase inhibitors |
| CN102603581B (en) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20081581A1 (en) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
| EP2161271A1 (en) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
| PE20120184A1 (en) | 2009-03-11 | 2012-03-28 | Plexxikon Inc | DERIVATIVES OF PYRROLO [2,3-B] PYRIDINE FOR THE INHIBITION OF RAF PROTEIN KINASES |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US9062076B2 (en) | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| CN102753549A (en) | 2009-12-23 | 2012-10-24 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
| MA34948B1 (en) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| US8791112B2 (en) | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| ES2725790T3 (en) | 2011-08-26 | 2019-09-27 | Neupharma Inc | Some chemical entities, compositions, and methods |
| TWI601725B (en) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |
| CN104812389B (en) | 2012-09-24 | 2020-07-17 | 润新生物公司 | Certain chemical entities, compositions, and methods |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| CN107106873A (en) | 2015-01-09 | 2017-08-29 | 吉利德阿波罗公司 | ACC inhibitor combined therapies for treating non-alcoholic fatty liver disease |
| US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
| MX2019008458A (en) | 2017-01-17 | 2019-12-02 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death. |
| KR20200051626A (en) | 2017-08-07 | 2020-05-13 | 조인트 스탁 컴퍼니 "바이오케드" | New heterocyclic compound as a CDK8 / 19 inhibitor |
| AU2019216264B2 (en) | 2018-01-31 | 2023-08-31 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| RU2678455C1 (en) | 2018-06-01 | 2019-01-29 | Сергей Викторович Леонов | N-(3-(5-(4-chlorophenyl)-1n-pyrazolo[3,4-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulphonamide crystalline form, active component, pharmaceutical composition and medicine |
| EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3104246A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| SG11202102208WA (en) | 2018-09-04 | 2021-04-29 | Magenta Therapeutics Inc | Aryl hydrocarbon receptor antagonists and methods of use |
| EP3894392A4 (en) | 2018-12-11 | 2022-08-24 | Duke University | Compositions and methods for the treatment of cancer |
| US11370770B2 (en) | 2019-06-24 | 2022-06-28 | Northwestern University | 3-arylindazoles as selective MEK4 inhibitors |
| KR20220046584A (en) | 2019-07-29 | 2022-04-14 | 헤파레게닉스 게엠베하 | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocellular death |
| CN112778311A (en) | 2019-11-01 | 2021-05-11 | 上海翰森生物医药科技有限公司 | Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof |
| CA3164361A1 (en) | 2020-01-15 | 2021-07-22 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
| WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
-
2019
- 2019-01-30 AU AU2019216264A patent/AU2019216264B2/en active Active
- 2019-01-30 KR KR1020207021909A patent/KR20200138166A/en active Search and Examination
- 2019-01-30 EP EP19701674.4A patent/EP3746437A1/en active Pending
- 2019-01-30 IL IL276353A patent/IL276353B2/en unknown
- 2019-01-30 MX MX2020007954A patent/MX2020007954A/en unknown
- 2019-01-30 WO PCT/EP2019/052213 patent/WO2019149738A1/en active Application Filing
- 2019-01-30 BR BR112020015072-0A patent/BR112020015072A2/en unknown
- 2019-01-30 US US16/965,912 patent/US11858927B2/en active Active
- 2019-01-30 MA MA051889A patent/MA51889A/en unknown
- 2019-01-30 CA CA3089678A patent/CA3089678A1/en active Pending
- 2019-01-30 SG SG11202007143UA patent/SG11202007143UA/en unknown
- 2019-01-30 JP JP2020540553A patent/JP7337813B2/en active Active
- 2019-01-30 CN CN201980011310.4A patent/CN111788195B/en active Active
-
2023
- 2023-11-08 US US18/388,084 patent/US20240116931A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020125133A3 (en) | 2022-02-28 |
| AU2019216264B2 (en) | 2023-08-31 |
| IL276353B1 (en) | 2023-10-01 |
| US20240116931A1 (en) | 2024-04-11 |
| US20210078995A1 (en) | 2021-03-18 |
| IL276353B2 (en) | 2024-02-01 |
| RU2020125133A (en) | 2022-02-28 |
| BR112020015072A2 (en) | 2021-01-05 |
| CA3089678A1 (en) | 2019-08-08 |
| IL276353A (en) | 2020-09-30 |
| EP3746437A1 (en) | 2020-12-09 |
| WO2019149738A1 (en) | 2019-08-08 |
| KR20200138166A (en) | 2020-12-09 |
| MX2020007954A (en) | 2021-01-08 |
| CN111788195B (en) | 2023-11-21 |
| CN111788195A (en) | 2020-10-16 |
| JP7337813B2 (en) | 2023-09-04 |
| AU2019216264A1 (en) | 2020-08-13 |
| MA51889A (en) | 2021-05-05 |
| JP2021514346A (en) | 2021-06-10 |
| US11858927B2 (en) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276353A (en) | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| IL279641A (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| ZA201905078B (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| SG11202010183XA (en) | Pyridazinones as parp7 inhibitors | |
| IL290190A (en) | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| HK1256820A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
| ZA202108443B (en) | Protein tyrosine phosphatase inhibitors | |
| IL281108A (en) | Compositions and methods for enhancing donor oligonucleotide-based gene editing | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| DK3288931T4 (en) | CERTAIN PROTEIN KINASE INHIBITORS | |
| ZA202000107B (en) | Aminothiazole compounds as protein kinase inhibitors | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| IL290314A (en) | Quinoline derivatives as protein kinase inhibitors | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB202111043D0 (en) | Protein interaction inhibitors | |
| GB202110970D0 (en) | Protein interaction inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| EP3784240C0 (en) | Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof for treating wnt6-overexpressing glioblastoma | |
| IL278984A (en) | Safinamide for treating myotonia |